HUTCHMED (NASDAQ:HCM), a global biopharmaceutical company, announced today that its innovative cancer drug, ORPATHYS® (savolitinib), will continue to be included in China's National Reimbursement Drug List (NRDL) beyond January 1, 2025.
This extension ensures that patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations will continue to have access to this vital treatment option.
ORPATHYS®, an oral and highly selective MET tyrosine kinase inhibitor (TKI), was initially included in the NRDL in March 2023.
This latest renewal underscores the drug's significant clinical value and the Chinese government's commitment to improving patient access to innovative therapies.
The NRDL is a crucial mechanism in China's healthcare system, providing affordable access to essential medicines for a vast population.
By remaining on the list, ORPATHYS® will continue to benefit from government subsidies, making it more accessible to patients.